Social functioning and quality of life in the schizophrenic patient: advantages of amisulpride
- 1 January 2002
- journal article
- review article
- Published by Wolters Kluwer Health in International Clinical Psychopharmacology
- Vol. 17 (1) , 1-8
- https://doi.org/10.1097/00004850-200201000-00001
Abstract
Schizophrenia is associated with significant social, psychological and occupational dysfunction. Not only is this distressing for the patients and their family and friends, but it also results in high indirect costs. Reintegration back into society, one of the most important aspects of quality life for schizophrenic patients and their physicians, must therefore take into account a patient's social functioning and employability, as well as improvement in symptoms. Although the typical antipsychotics are effective in managing the positive symptoms of schizophrenia, they may not alleviate other aspects of the disorder. They are also associated with extrapyramidal symptoms and other severe adverse events that have significant consequences for quality of life and compliance. The atypical antipsychotic, amisulpride, has an improved safety and tolerability profile and has been shown to be significantly more effective than placebo and haloperidol on a number of quality of life and social functioning scales, including the Global Assessment of Functioning, the Quality of Life Scale, the Functional Status Questionnaire and the Psychosocial Aptitude Rating Scale. In conclusion, amisulpride, in addition to its proven clinical efficacy, may help reintegration of the schizophrenic patient back into society.Keywords
This publication has 20 references indexed in Scilit:
- Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group*European Psychiatry, 2000
- Long-term safety and efficacy of amisulpride in subchronic or chronic schizophreniaInternational Clinical Psychopharmacology, 2000
- Safety of amisulpride (Solian??): a review of 11 clinical studiesInternational Clinical Psychopharmacology, 1999
- Atypical Antipsychotics: Part II Adverse Effects, Drug Interactions, and CostsAnnals of Pharmacotherapy, 1999
- Olanzapine Versus Placebo and Haloperidol: Quality of Life and Efficacy Results of the North American Double-Blind TrialNeuropsychopharmacology, 1998
- Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patientsThe British Journal of Psychiatry, 1997
- Treatment of Negative Symptoms in Schizophrenia with AmisulprideThe British Journal of Psychiatry, 1995
- The Positive and Negative Syndrome Scale (PANSS) for SchizophreniaSchizophrenia Bulletin, 1987
- The functional status questionnaireJournal of General Internal Medicine, 1986
- The Quality of Life Scale: An Instrument for Rating the Schizophrenic Deficit SyndromeSchizophrenia Bulletin, 1984